Short Interest in Centogene (NASDAQ:CNTG) Drops By 20.1%
Short Interest in Centogene (NASDAQ:CNTG) Drops By 20.1%
Centogene (NASDAQ:CNTG – Get Rating) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 18,700 shares, a decrease of 20.1% from the June 30th total of 23,400 shares. Approximately 0.3% of the company's shares are sold short. Based on an average daily volume of 9,600 shares, the short-interest ratio is currently 1.9 days.
Centogene(纳斯达克:CNTG-GET Rating)是空头股数7月份大幅下降的目标。截至7月15日,空头股数共有18,700股,较6月30日的23,400股减少20.1%。该公司约0.3%的股票被卖空。以日均成交量9,600股计算,短息比率目前为1.9天。
Centogene Stock Performance
世纪之交股票表现
NASDAQ CNTG opened at $1.55 on Thursday. The company has a market capitalization of $30.78 million, a price-to-earnings ratio of -0.64 and a beta of -1.18. Centogene has a twelve month low of $1.34 and a twelve month high of $11.61. The stock has a fifty day simple moving average of $2.24 and a 200 day simple moving average of $3.30. The company has a quick ratio of 2.41, a current ratio of 2.48 and a debt-to-equity ratio of 0.67.
新浪纳斯达克周四开盘价为1.55美元。该公司市值为3,078万美元,市盈率为-0.64倍,贝塔系数为-1.18。Centogene的12个月低点为1.34美元,12个月高位为11.61美元。该股的50日简单移动均线为2.24美元,200日简单移动均线为3.30美元。该公司的速动比率为2.41,流动比率为2.48,债务权益比率为0.67。
Centogene (NASDAQ:CNTG – Get Rating) last issued its quarterly earnings results on Friday, July 15th. The company reported ($0.54) earnings per share for the quarter. Centogene had a negative return on equity of 134.55% and a negative net margin of 35.35%. The business had revenue of $11.59 million for the quarter. Sell-side analysts expect that Centogene will post -1.72 EPS for the current year.
Centogene(纳斯达克:CNTG-GET Rating)上一次发布季度收益报告是在7月15日(星期五)。该公司公布了本季度每股收益(0.54美元)。Centogene的净资产回报率为负134.55%,净利润率为负35.35%。该业务本季度的收入为1159万美元。卖方分析师预计,Centogene本年度每股收益将达到1.72欧元。
Institutional Trading of Centogene
世纪之交的机构交易
Analyst Ratings Changes
分析师评级发生变化
Separately, SVB Leerink decreased their price objective on Centogene from $10.00 to $6.00 and set an "outperform" rating for the company in a report on Monday, July 18th.
另外,SVB Leerink在7月18日周一的一份报告中将Centogene的目标价从10.00美元下调至6.00美元,并为该公司设定了“跑赢大盘”的评级。
Centogene Company Profile
Centogene公司简介
(Get Rating)
(获取评级)
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.
Centogene N.V.及其子公司专注于罕见疾病,将现实世界的临床和基因或其他数据转换为可操作的信息,供世界各地的患者、医生和制药公司使用。它通过三个部门运作:制药、诊断和新冠肺炎测试。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Centogene (CNTG)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn't Ignore
- 免费获取StockNews.com关于Centogene的研究报告(CNTG)
- 有不同类型的股票可供投资
- 是时候开发Molson Coors了,还是啤酒销售会变得平淡?
- 星巴克是在向月球进军吗?
- PayPal继续挣扎,竞争加剧
- 你不应该忽视的两个高收益深度价值
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.
接受《世纪英文报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Centogene和相关公司的最新新闻和分析师评级的每日简要摘要。